rxstat › Classes › Antiglaucoma Preparations And Miotics
Antiglaucoma Preparations And Miotics: shortage status in Canada
14 of the 19 antiglaucoma preparations and miotics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.
Levobunolol (Betagan) Widespread shortage 2 of 4 reported products affected
Pilocarpine (Isopto Carpine) Widespread shortage 4 of 6 reported products affected
Timolol (Timoptic-Xe) Widespread shortage 6 of 12 reported products affected · est. return Jul 30, 2027
Timolol Brimonidine (Combigan) Widespread shortage 2 of 3 reported products affected · est. return Jan 8, 2027
Timolol Travoprost (Duotrav Pq) Widespread shortage 2 of 2 reported products affected · est. return Oct 19, 2026
Travoprost (Travatan Z) Widespread shortage 3 of 6 reported products affected · est. return Oct 23, 2026
Acetazolamide Partial shortage 1 of 3 reported products affected · est. return Jan 1, 2027
Acetylcholine Chloride (Miochol-E) Partial shortage 1 of 1 reported products affected · est. return Dec 20, 2026
Bimatoprost (Vistitan) Partial shortage 1 of 2 reported products affected
Brimonidine (Alphagan P) Partial shortage 2 of 9 reported products affected · est. return Jan 15, 2027
Dipivefrin Partial shortage 1 of 1 reported products affected
Latanoprost (Xalatan) Partial shortage 2 of 11 reported products affected
Timolol Dorzolamide (Cosopt) Partial shortage 1 of 11 reported products affected
Timolol Latanoprost (Xalacom) Partial shortage 4 of 9 reported products affected · est. return Jun 30, 2027
Carbachol (Miostat Ophthalmic) Shortage anticipated 0 of 1 reported products affected
Apraclonidine (Iopidine) No current shortage
Betaxolol (Betoptic S) Discontinued 0 of 1 reported products affected
Dorzolamide (Trusopt) No current shortage
Methazolamide No current shortage
Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.